Let’s Talk About CRISPR Therapeutics AG (NASDAQ: CRSP)’s Outlook

In the last trading session, 1.48 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.76. With the company’s per share price at $38.68 changed hands at -$0.09 or -0.23% during last session, the market valuation stood at $3.34B. CRSP’s last price was a discount, traded about -75.49% off its 52-week high of $67.88. The share price had its 52-week low at $30.04, which suggests the last value was 22.34% up since then.

Analysts gave the CRISPR Therapeutics AG (CRSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.87. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CRSP as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.

CRISPR Therapeutics AG (NASDAQ:CRSP) trade information

Instantly CRSP was in red as seen at the end of in last trading. With action 2.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -1.73%, with the 5-day performance at 2.90% in the green. However, in the 30-day time frame, CRISPR Therapeutics AG (NASDAQ:CRSP) is 2.41% up.

The consensus price target for the stock as assigned by Wall Street analysts is 65, meaning bulls need an upside of 40.49% from its current market value. According to analyst projections, CRSP’s forecast low is 65 with 65 as the target high. To hit the forecast high, the stock’s price needs a -68.05% plunge from its current level, while the stock would need to soar -68.05% for it to hit the projected low.

CRISPR Therapeutics AG (CRSP) estimates and forecasts

The 2025 estimates are for CRISPR Therapeutics AG earnings to decrease by -22.51%, but the outlook for the next 5-year period is at 7.02% per year.

CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders

ARK INVESTMENT MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.1597% or 7.78 million shares worth $420.12 million as of 2024-06-30.

Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Innovation ETF and NEW PERSPECTIVE FUND. With 6.34 shares estimated at $245.29 million under it, the former controlled 7.34% of total outstanding shares. On the other hand, NEW PERSPECTIVE FUND held about 2.96% of the shares, roughly 2.55 shares worth around $98.76 million.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.